To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for treating extensive stage small-cell lung cancer
Status In progress
Process STA 2018
ID number 1618

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 16 August 2019 - 16 September 2019

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 May 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance